Polyrizon Ltd. leverages two proprietary hydrogel platforms—C&C and T&T—to develop nasal sprays acting as physical barriers and sustained drug delivery systems. Despite promising technology with distinct regulatory pathways via FDA Class II medical device designations, the firm’s operating losses deepened substantially in fiscal 2025, reflecting increased clinical development expenses. Strong liquidity cushions current cash burn, but regulatory uncertainty, competition from entrenched pharmaceutical players, and recent operational setbacks necessitate close monitoring of clinical milestones and capital management. Upcoming results from US clinical trials and regulatory submissions remain critical to the company’s growth trajectory.